BAL30072, a novel siderophore (iron-binding) sulfactam antibiotic, was developed for the patients who were suffering from infections caused by multidrug-resistant Gram-negative bacteria.
The Phase I study assessed the safety, tolerability and pharmacokinetics of single ascending doses of BAL30072 in healthy volunteers.
The trial results also demonstrated dose-proportional plasma levels as well as linear pharmacokinetic properties.
Basilea CEO Anthony Man said these results support the potential of BAL30072 as a new treatment option for severe and life- threatening infections caused by multidrug-resistant Gram-negative bacteria, where currently very limited therapeutic options exist.